CASEY COPE: Open Payments
NPI 1073090528 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$648 in 43 payments from 16 companies in 2025. Trend: 2023 $425 · 2024 $717 · 2025 $648
Food & beverage: $648
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $176 |
| Amgen Inc. | 12 | $143 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
| Novo Nordisk Inc | 1 | $25 |
| Boston Scientific Corporation | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
Products named: LEQVIO, REPATHA, DUPIXENT, Kerendia, CAMZYOS, Ozempic, WATCHMAN FLX, AMVUTTRA.
Industry payments across MO — which companies pay providers there.
